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Chikungunya virus (CHIKV), a mosquitoborne alpha-
virus, is endemic in Africa and Asia. In 2005–2006, CHIKV 
epidemics were reported in islands in the Indian Ocean and 
in southern India. We present data on laboratory-conﬁ  rmed 
CHIKV infections among travelers returning from India to 
the United States during 2006.
C
hikungunya virus (CHIKV) is a mosquito-transmitted 
virus (genus Alphavirus, family Togaviridae) usually 
associated with acute epidemic polyarthralgia. The virus 
is serologically and genetically most closely related to 
o’nyong-nyong, Igbo Ora, and, to a lesser extent, Mayaro 
and Ross River viruses, all of which are associated with 
acute polyarthralgia (1). 
CHIKV epidemics have been described in Africa, 
the Middle East, India, and Southeast Asia, and may have 
caused epidemics in the Caribbean and in the United States 
during the early 19th century (2). CHIKV epidemics can 
be explosive with large numbers of human cases and rapid 
virus dissemination. In the Réunion Island epidemic from 
April 2005 to June 2006, ≈270,000 cases were reported, 
representing nearly 40% of the population (3). Aedes ae-
gypti is the principal vector; however, in recent epidemics 
in Réunion Island and southern India, Ae. albopictus has 
been co-implicated (4,5). In Africa, CHIKV is maintained 
in an enzootic cycle involving primates, but in Asia and 
in recent large epidemics, the human-mosquito cycle pre-
dominates, possibly including mechanical transmission (6). 
Symptoms are characterized by acute onset of joint pain, 
followed by myalgia, fever, and rash with recovery usually 
within weeks.
Laboratory diagnosis of CHIKV infection is accom-
plished by serologic methods, virus isolation, and reverse 
transcription–PCR (RT-PCR). A typical serologic algo-
rithm involves testing acute- and convalescent-phase serum 
specimens for immunoglobulin M (IgM) and IgG antibody, 
followed by a plaque reduction neutralization test (PRNT). 
Virus isolation and RT-PCR are normally used with early 
acute-phase specimens (before day 5 post-onset) because 
duration of viremia is typically 2–4 days.
Recent CHIKV outbreaks have been reported in sev-
eral islands in the Indian Ocean as well as in southern India, 
where >1 million cases were reported in 2006 (4,7). CHIKV 
infections have also been documented in travelers returning 
from these areas (3,7). We report conﬁ  rmed CHIKV infec-
tions among 35 travelers returning from overseas travel; 
33 were returning from India and 2 from Réunion Island 
(Table 1). 
The Study
Serum samples were received by the Centers for Dis-
ease Control and Prevention (Fort Collins, CO, USA) from 
April 2006 to December 2006 as part of routine diagnostic 
and reference services available to public health labora-
tories. A total of 106 serum samples were received from 
persons returning from regions with epidemics or where 
CHIKV is endemic (79 from India and the Indian Ocean 
islands and 27 from Africa) with compatible CHIKV ill-
ness and submitted by state public health laboratories. Se-
rum samples were tested for antibodies to several viruses 
known to occur in the region of travel and residence by 
IgM capture ELISA and a standard IgG ELISA (8,9). The 
35 CHIKV IgM- and IgG-positive specimens were tested 
by using a PRNT (90% reduction cutoff) with several re-
lated alphaviruses (Sindbis, o’nyong-nyong, and Semliki 
Forest viruses) to conﬁ  rm speciﬁ  city of reactivity (10). 
A ≥4-fold neutralizing titer difference between antibody 
to CHIKV and antibodies to other alphaviruses indicated 
a CHIKV-speciﬁ   c antibody response. IgM-positive and 
PRNT speciﬁ  city–conﬁ  rmed specimens were classiﬁ  ed as 
recent CHIKV infections (Table 1).
All serum specimens were tested by a quantitative, 
real-time,  ﬂ   uorescent probed–based RT-PCR assay for 
CHIKV RNA. Two primer probe sets were designed in 
unique regions of the viral genome and reacted speciﬁ  cally 
with CHIKV RNA and not with related or unrelated vi-
ruses (Table 2). Both sets showed an analytical sensitivity 
<1 PFU, and CHIKV was detected in virus-spiked serum 
samples at a concentration of 10 PFU/mL (75 μL of serum 
assayed). Eight serum specimens showed positive results 
by the real-time assay; all were acute-phase specimens with 
number of days post-onset of illness reported as <6. Viral 
titers of these specimens were estimated by quantitative 
RT-PCR that used CHIKV quantity standards (determined 
by plaque assay) to generate a standard curve. Titers of 8 
specimens ranged from 103.9 PFU/mL to 106.8 PFU/mL. 
All acute-phase specimens (on or before day 8 poston-
set) were also tested for CHIKV by virus isolation in Vero 
cells. Isolation was performed by using a recently developed 
protocol in which cells were grown in glass shell vials and 
centrifuged to enhance viral infectivity (J.O. Velez, unpub. 
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data). Five serum specimens displayed prominent and char-
acteristic cytopathic effect on day 2 postinfection, and virus 
was identiﬁ  ed as CHIKV by RT-PCR. All virus isolates 
were obtained from acute-phase specimens that also were 
positive by RT-PCR. Three serum specimens (samples 2, 8, 
and 10) showed positive RT-PCR results, but CHIKV was 
not isolated from these specimens. In these 3 specimens, in-
ability to isolate virus may have been related to viral titers, 
which were lower than most of the virus isolation–positive 
samples, or to handling or storage of these samples. All 
8 virus-positive specimens (whether positive by RT-PCR, 
virus isolation, or both) were collected <7 days post-onset 
and were negative for IgM and IgG antibodies to CHIKV. 
Nearly all of the specimens collected <7 days post-onset 
were positive by 1 of the virus-based tests. The 2 excep-
tions, samples 1 and 9, were positive for IgM and IgG an-
tibodies to CHIKV and had high PRNT titers. These ﬁ  nd-
ings indicate that these samples were not true acute-phase 
specimens; the true onset or collection date had likely been 
reported incorrectly.
To identify the strain of CHIKV in these specimens, 
a 2,122-bp fragment from the structural region of the ge-
nome (nucleotide positions 9,648–11,770) was ampliﬁ  ed 
from all 8 virus-positive specimens by RT-PCR and sub-
jected to nucleic acid sequencing with previously described 
primers (11). All 8 sequences showed nucleotide identity 
Table 1. Diagnostic test results for 35 travelers infected with chikungunya virus (CHIKV), 2006* 
Sample
IgM
ELISA†
IgG
ELISA† PRNT‡
Virus
isolation
(Vero
cells) 
RT-
PCR§
Viremia,
PFU/mL¶ 
Days from 
onset of 
illness 
to collection 
State of US 
residence Return date, 2006
1 17.7 3.2 640 – – NA 0 NJ 10/12
2 1.7 1.7 <10 – + 10
4.0 1 CA Before 11/28 
31 . 2 1 . 1 N D + + 1 0
4.1 1I L 9 / 2 9
4 1.8 NS ND + + 10
6.8 2C A B e f o r e 9 / 1 6
5 1.2 0.76 ND + + 10
5.1 2M A 9 / 1 0
6 1.8 1.6 <10 + + 10
6.0 3P A B e f o r e 8 / 2 0
71 . 6 1 . 2 N D + + 1 0
5.3 3C A 1 0 / 2
8N S 1 . 4 N D – + 1 0
3.9 4 WI 10/9
9 22.0 4.3 5,120 – – NA 4 CA Before 10/6
10 1.1 0.95 <10 – + 10
4.5 6C A B e f o r e 8 / 1 3
11 7.4 0.96 40 – – NA 7 CA Before 9/23
12 15.0 0.60 320 – – NA 8 CT Before 7/6
13 26.2 1.2 160 ND – NA 8 DC Before 10/16 
14 12.9 5.8 1,80 ND – NA 10 CA Before 9/22
15 38.8 2.3 2,560 ND ND NA 19 CT Before 7/6 
16 12.7 1.5 640 ND – NA 20 IL 8/23
17 16.9 4.8 640 ND – NA 30 IL 6/25
18 8.3 3.7 640 ND ND NA 31 HI Before 8/2
19 6.6 1.5 640 ND – NA 31 CA Before 8/13
20 2.6 6.8 320 ND – NA 34 MD Before 3/20
21 5.0 NS 640 ND – NA 34 IL Before 9/22
22 15.1 4.1 1,280 ND – NA 38 CA Before 10/2
23 4.3 5.9 2,560 ND – NA 42 PA Before 8/20
24 5.6 NS 320 ND – NA 43 Unknown Unknown 
25 3.1 3.7 640 ND – NA 44 IL Before 9/12
26 26.6 13.4 5,120 ND ND NA 48 SC 6/24
27 30.7 6.6 5,120 ND – NA 61 CA Before 10/26 
28 6.1 11.4 2,560 ND – NA 62 CT Before 10/3
29 9.4 16.0 640 ND – NA 63 CA 8/23
30 7.5 8.4 1,280 ND – NA 71 MN 6/8
31 5.3 5.8 640 ND – NA 71 MN 6/8
32 3.7 16.1 320 ND – NA 75 LA Before 3/30
33 9.8 10.1 2,560 ND – NA 92 IL 7/9
34 7.5 3.1 160 ND – NA 101 PA Before 10/13 
35 24.6 11.9 20,480 ND – NA Unknown IL Before 11/08 
*IgM, immunoglobulin M; PRNT, plaque reduction neutralization test; RT-PCR, reverse transcription–PCR; NA, not applicable; ND, not done 
(sample depleted); NS, nonspecific reaction in ELISA. 
†Values are patient sample optical densities divided by a negative control optical density; values >3 are positive. 
‡Values are 90% plaque reduction neutralization titers. 
§Real-time, fluorescence-based assay for detecting CHIKV RNA; positive samples had crossing threshold values <37 with both primer sets. 
¶Estimated CHIKV PFU/mL by real-time RT-PCR using a standard curve generated with plaque-titrated/calibrated CHIKV standards. DISPATCHES
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>99.7% (GenBank accession nos. EF451142–EF451149). 
BLAST analysis (www.ncbi.nlm.nih.gov/blast) of the 8 se-
quences showed that the highest percentage identity was to 
CHIKV strains recently isolated from travelers returning 
from Indian Ocean islands (Réunion, Mauritius, and Sey-
chelles). Percentage identity matches between the 8 viruses 
and Indian Ocean CHIKV strains were >99.5%, with 5 to 
8 mismatches occurring randomly. In comparison, percent-
age identities of the 8 viruses to CHIKV prototype S27 or 
to a strain previously isolated from India (Nagpur/653496) 
were 95.1% and 94.4%, respectively.
Conclusions
The data reported conﬁ  rm that the widespread CHIKV 
epidemic in southern India has infected US travelers. 
CHIKV infections among international travelers are not 
unexpected; in 2005–2006, ≈800 CHIKV infections were 
reported in France, primarily in travelers returning from 
Réunion Island (3). The more noteworthy observation of 
this study with potential public health ramiﬁ  cations is that 
high levels of infectious virus were detected in returning 
travelers. Primary vectors for CHIKV are Ae. aegypti and 
Ae. albopictus, which are established in several southeast-
ern coastal states in the United States. Vector competence 
studies of Ae. aegypti and Ae. albopictus strains from the 
United States, as well as strains from the Caribbean and 
South America, showed that a titer of ≈104 PFU/mL in 
monkeys resulted in productive infection with virus dis-
semination in these mosquitoes, with Ae. albopictus show-
ing higher infection and dissemination rates (12). The level 
of viremia reported in most of these imported CHIKV in-
fections, >104 PFU/mL, could be sufﬁ  cient to infect North 
American vectors, given the appropriate environmental 
conditions. However, the time of year and place of resi-
dence of the returning travelers in this study were not con-
ducive to transmission; only 2 (patients 26 and 32) returned 
to US regions (South Carolina and Louisiana) known to 
have populations of Ae. albopictus.
Nevertheless, returning travelers with high viremia 
levels, who live in areas with established Ae. aegypti and 
Ae. albopictus populations, could facilitate local transmis-
sion in the United States. Clinicians should therefore obtain 
travel histories from persons with CHIKV-compatible ill-
ness and include CHIKV in differential diagnoses when ap-
propriate. Public health laboratories must carefully moni-
tor CHIKV infections of returning travelers and conduct 
surveillance for CHIKV-infected vectors in high-risk areas 
to prevent local establishment of a new emerging virus. 
Diagnostic laboratory personnel involved in virus isola-
tion protocols must be aware of the potential of isolating 
CHIKV (a biosafety level 3 agent) from patients returning 
from regions endemic for CHIKV or regions with epidem-
ics and take appropriate safety precautions.
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